<DOC>
	<DOCNO>NCT01646320</DOCNO>
	<brief_summary>The purpose study learn BMS-512148 ( Dapagliflozin ) part triple combination therapy improve ( decrease ) hemoglobin A1c patient type 2 diabetes 24 week treatment compare 2 drug oral antidiabetic therapy . The safety treatment also study .</brief_summary>
	<brief_title>Safety Efficacy Dapagliflozin Triple Therapy Treat Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>Prior randomization , eligible subject receive open-label treatment Saxagliptin 5mg Metformin IR 16-week open-label treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion Criteria 1 . Signed Written Informed Consent 1 . Subjects must willing able give sign date write informed consent . 2 . Target Population For inclusion Stratum A : ) Subjects T2DM inadequate glycemic control , define central laboratory HbA1c ≥ 8.0 ≤ 11.5 % obtain screen visit ( ie Week 18 visit ) , stable metformin therapy alone least 8 week prior screen visit dose ≥ 1500 mg per day For inclusion Stratum B : ii ) Subjects T2DM inadequate glycemic control , HbA1c ≥ 7.5 ≤ 10.5 % obtain screen visit stable metformin therapy dose ≥ 1500 mg per day AND DPP4 inhibitor maximum approve dose least 8 week prior screen visit . b ) Cpeptide ≥ 1.0 ng/mL ( 0.34 nmol/L ) screen visit . c ) BMI ≤ 45.0 kg/m2 screen visit . 3 . Age Reproductive Status 1 . Men woman , age ≥ 18 year old time screen visit . 2 . Women childbearing potential ( WOCBP ) must use acceptable method contraception avoid pregnancy throughout study manner risk pregnancy minimize . 3 . WOCBP must negative serum urine pregnancy test within 24 hour prior start investigational product . 4 . Women must breastfeed 5 . Sexually active fertile men must use highly effective birth control partner WOCBP . Exclusion Criteria 1 . Target Disease Exceptions 1 . History diabetes insipidus 2 . Symptoms poorly control diabetes would preclude participation trial include limited mark polyuria polydipsia great 10 % weight loss three month prior screen , sign symptom . 3 . History diabetic ketoacidosis hyperosmolar nonketotic coma . 2 . Medical History Concurrent Diseases 1 . History bariatric surgery lapband procedure within 12 month prior screen . 2 . Any unstable endocrine , psychiatric rheumatic disorder judge Investigator . 3 . Subject , judgment investigator , may risk dehydration volume depletion may affect interpretation efficacy safety data concomitant use loop diuretic country recognize Dapagliflozin label . 4 . Subject currently abuse alcohol drug do within last 6 month . Acute Vascular Event : 5 . Uncontrolled hypertension define systolic blood pressure ( SBP ) ≥ 160 mmHg and/or diastolic blood pressure ( DBP ) ≥ 100 mmHg . 6 . Cardiovascular Disease within 3 month screen visit [ ie myocardial infarction , cardiac surgery revascularization ( CABG/PTCA ) , unstable angina , stroke transient ischemic attack ( TIA ) ] . 7 . Congestive heart failure New York Association ( NYHA ) class IV , unstable acute congestive heart failure . Renal Diseases : 8 . Moderate severe impairment renal function [ define eGFR &lt; 60 mL/min/1.73m2 ( estimate MDRD ) serum creatinine ( Scr ) ≥ 1.5 mg/dL male ≥ 1.4 mg/dL female . ] 9 . Conditions congenital renal glucosuria Hepatic Diseases : 10 . Significant hepatic disease , include , limited , chronic active hepatitis and/or severe hepatic insufficiency , include subject ALT and/or AST &gt; 3x ULN Total Bilirubin &gt; 2.5 x ULN . Hematological Oncological Disease/Conditions : 11 . History hemoglobinopathy , exception sickle cell trait ( SA ) thalassemia minor ; chronic recurrent hemolysis . 12 . Malignancy within 5 year screen visit ( exception treat basal cell treat squamous cell carcinoma ) 13 . Known immunocompromised status , include limited , individual undergo organ transplantation positive human immunodeficiency virus . 14 . Donation blood blood product blood bank , blood transfusion , participation clinical study require withdrawal &gt; 400 mL blood 6 month prior screen visit . Prohibited treatment therapy : 15 . Administration antihyperglycemic therapy , metformin DPP4 's , 14 day ( consecutive ) 12 week prior screen , well previous exposure DPP4 SGLT2 inhibitor DPP4 SGLT2 inhibitor trial exclusion criterion . 16 . Current treatment potent cytochrome P450 3A4/5 inhibitor ( country dose adjustment would require dapagliflozin label ) . 17 . Administration investigational drug participation interventional clinical study within 30 day plan screen study . Subjects fail satisfy eligibility criterion screen enter leadin openlabel period CV181168 CV181169 study specifically , need wait 30 day . 3 . Physical Laboratory Test Findings ) Hemoglobin ≤ 11.0 g/dL ( 110 g/L ) men ; hemoglobin ≤ 10.0 g/dL ( 100 g/L ) woman b ) Presence hematuria : ) For male subject consider Stratum A : microscopic hematuria present Week 18 Week 16 AND common cause confirm exclusionary . Male subject confirm common cause enter openlabel phase document negative result hematuria microscopic urinalysis perform central laboratory . ii ) For male subject consider Stratum B : microscopic hematuria present Week 10 Week 8 AND common cause confirm exclusionary . Male subject confirm common cause enter openlabel phase document negative result hematuria microscopic urinalysis perform central laboratory . NOTE : Female sub } ects hematuria enter openlabel phase randomize , investigate accord local standard best clinical practice . ( See Appendix 3 ) c ) Other central laboratory test finding : − Abnormal free T4 value . Abnormal thyroid stimulate hormone ( TSH ) value screen evaluate free T4 . Sub } ects abnormal free T4 value exclude . Positive hepatitis B surface antigen Positive antihepatitis C virus antibody 4 . Allergies Adverse Drug Reaction ) Subjects contraindication therapy outline dapagliflozin saxagliptin Investigator Brochure , local dapagliflozin saxagliptin package insert local metformin package insert , include current treatment potent cytochrome P450 3A4/5 inhibitor ( country dose adjustment would require local Onglyza ( saxagliptin ) label . 5 . Sex Reproductive Status ) Women pregnant 6 . Other Exclusion Criteria 1 . Prisoners subject involuntarily incarcerate 2 . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness 3 . Subjects commercial weight loss program ongoing weight loss , intensive exercise program . 4 . Employee BMS , AstraZeneca ( AZ ) , relatives . 5 . Subject condition , judgment Investigator , may render subject unable complete study may pose significant risk subject . 6 . Subject participate investigator , study coordinator , employee investigator immediate family member aforementioned . Open Label Treatment Period Note : Enrollment subject openlabel ( Stratum A ) treatment period , begin eee 16 study HbA1c value low bound ( ≥ 8.0 % ≤ 9.0 % ) Enrollment subject openlabel ( Stratum B ) eee 8 , study HbA1c value low bound ( ≥ 7.5 % ≤ 8.5 % ) limit approximately 50 % total number subject randomize . • For subject Stratum A : At Week 10 Week 2 FPG qualification check perform . Subjects central laboratory FPG value meeting &gt; 270 mg/dL schedule followup visit ( within 3 5 day ) obtain second central laboratory FPG value . If mean originally schedule central laboratory FPG repeat central laboratory FPG value &gt; 270 mg/dL , subject randomize must discontinue . For subject Stratum B : At Week 2 FPG qualification check perform . Subjects central laboratory FPG value meeting &gt; 270 mg/dL schedule followup visit ( within 3 5 day ) obtain second central laboratory FPG value . If mean originally schedule central laboratory FPG repeat central laboratory FPG value &gt; 270 mg/dL , subject randomize must discontinue Double Blind Treatment Period Inclusion criterion : • For Stratum A AND Stratum B : − Subjects T2DM inadequate glycemic control , define central laboratory HbA1c ≥ 7.0 ≤ 10.5 % obtain Week 2 visit openlabel treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>